ID: ALA3985747

Max Phase: Preclinical

Molecular Formula: C45H51ClN8O6S

Molecular Weight: 867.47

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN1CCN(Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3ccc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1

Standard InChI:  InChI=1S/C45H51ClN8O6S/c1-45(2)16-14-33(39(29-45)31-4-6-34(46)7-5-31)30-51-20-22-52(23-21-51)35-8-11-38(43(27-35)60-36-9-12-40-32(26-36)15-17-47-40)44(55)49-61(58,59)37-10-13-41(42(28-37)54(56)57)48-53-24-18-50(3)19-25-53/h4-13,15,17,26-28,47-48H,14,16,18-25,29-30H2,1-3H3,(H,49,55)

Standard InChI Key:  YMCICBCGKZKBRE-UHFFFAOYSA-N

Associated Targets(Human)

Apoptosis regulator Bcl-2 3787 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Apoptosis regulator Bcl-2 542 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Bcl-2-like protein 1 598 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 867.47Molecular Weight (Monoisotopic): 866.3341AlogP: 8.00#Rotatable Bonds: 12
Polar Surface Area: 156.39Molecular Species: ACIDHBA: 11HBD: 3
#RO5 Violations: 3HBA (Lipinski): 14HBD (Lipinski): 3#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.15CX Basic pKa: 7.96CX LogP: 6.95CX LogD: 7.14
Aromatic Rings: 5Heavy Atoms: 61QED Weighted: 0.08Np Likeness Score: -0.99

References

1.  (2015)  Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, 
2.  (2015)  Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, 

Source

Source(1):